Tablet manufacturing capacity expansion enhances supply resilience

The tablet manufacturing capacity expansion at Hovione’s Loures (Portugal) campus completes a multi-year capital program exceeding 40 million euros, integrating continuous and batch processing technologies to increase both production volume and operational flexibility for complex formulations while strengthening export capabilities to leading global pharmaceutical companies.

Dual Processing Technologies

Advanced continuous manufacturing platforms installed in 2022 are now complemented by a new batch production line with contemporary process controls. These dual approaches allow volume adjustments according to individual project specifications without compromising quality standards. The combined technological framework directly enables the site to handle diverse medication categories and production scales within a single integrated campus, further advancing the tablet manufacturing capacity expansion.

Workforce and Footprint Growth

The 25 percent enlargement of manufacturing floor space, together with the addition of fifty qualified roles across production, engineering, and quality functions, builds upon an existing workforce of roughly 1,250 employees. This incremental capacity follows earlier continuous-process investments and extends the facility’s ability to support both small-scale development and larger commercial campaigns.

Ad

Supply Chain Resilience

Enhanced manufacturing flexibility contributes to more resilient supply arrangements positioned closer to major markets, thereby supporting faster progression of new therapies through development stages. For health economics and outcomes research, these attributes reduce risks associated with supply disruptions that can affect market access timelines and reimbursement negotiations. The expansion therefore provides a concrete illustration of how targeted capital deployment in specialized production assets can underpin stable delivery of complex medications to patients worldwide.